lapatinib has been researched along with fluorodeoxyglucose f18 in 3 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (fluorodeoxyglucose f18) | Trials (fluorodeoxyglucose f18) | Recent Studies (post-2010) (fluorodeoxyglucose f18) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 34,771 | 2,160 | 20,111 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebi, H; Kawada, K; Kojima, Y; Minami, H; Mukai, H; Murakami, K; Sato, T; Shimokata, K; Tahara, M | 1 |
| Aktan, G; Baselga, J; Coccia-Portugal, MA; Cortés, M; Cure, H; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Fauria, K; Flamen, P; Gámez, C; Garcia, C; Gebhart, G; Holmes, E; Kim, SB; Piccart, M; Robles, J; Van Dooren, V; Vuylsteke, P | 1 |
| Arteaga, CL; Barry, WT; Dees, EC; Falkson, CI; Guo, H; Hobday, TJ; Krop, IE; Lin, NU; Mayer, IA; Najita, JS; Nanda, R; Richardson, AL; Rimawi, MF; Ryabin, N; Van den Abbeele, AD; Winer, EP; Wolff, AC; Yap, JT | 1 |
3 trial(s) available for lapatinib and fluorodeoxyglucose f18
| Article | Year |
|---|---|
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2013 |
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |